Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Detalles Bibliográficos
Autores principales: Rosell, Rafael, Filipska, Martyna, Chaib, Imane, Lligé, David, Laguia, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511626/
https://www.ncbi.nlm.nih.gov/pubmed/33014853
http://dx.doi.org/10.3389/fonc.2020.01726
_version_ 1783585993770663936
author Rosell, Rafael
Filipska, Martyna
Chaib, Imane
Lligé, David
Laguia, Fernando
author_facet Rosell, Rafael
Filipska, Martyna
Chaib, Imane
Lligé, David
Laguia, Fernando
author_sort Rosell, Rafael
collection PubMed
description
format Online
Article
Text
id pubmed-7511626
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75116262020-10-02 Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer Rosell, Rafael Filipska, Martyna Chaib, Imane Lligé, David Laguia, Fernando Front Oncol Oncology Frontiers Media S.A. 2020-09-10 /pmc/articles/PMC7511626/ /pubmed/33014853 http://dx.doi.org/10.3389/fonc.2020.01726 Text en Copyright © 2020 Rosell, Filipska, Chaib, Lligé and Laguia. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Rosell, Rafael
Filipska, Martyna
Chaib, Imane
Lligé, David
Laguia, Fernando
Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
title Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
title_full Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
title_fullStr Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
title_full_unstemmed Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
title_short Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
title_sort commentary: safety and feasibility of crispr-edited t cells in patients with refractory non-small-cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511626/
https://www.ncbi.nlm.nih.gov/pubmed/33014853
http://dx.doi.org/10.3389/fonc.2020.01726
work_keys_str_mv AT rosellrafael commentarysafetyandfeasibilityofcrispreditedtcellsinpatientswithrefractorynonsmallcelllungcancer
AT filipskamartyna commentarysafetyandfeasibilityofcrispreditedtcellsinpatientswithrefractorynonsmallcelllungcancer
AT chaibimane commentarysafetyandfeasibilityofcrispreditedtcellsinpatientswithrefractorynonsmallcelllungcancer
AT lligedavid commentarysafetyandfeasibilityofcrispreditedtcellsinpatientswithrefractorynonsmallcelllungcancer
AT laguiafernando commentarysafetyandfeasibilityofcrispreditedtcellsinpatientswithrefractorynonsmallcelllungcancer

Ejemplares similares